BioCorRx, Inc. Announces Launch of Pilot Program with Louisiana Department of Corrections for Offenders Suffering with Alcohol and Opioid Use Disorders
ANAHEIM, CA, May 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx®”)(“Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announces treatment of the first patient in its partnership with the Louisiana Department of Corrections (LADOC) in its Recovery Program Pilot. Doctors from the Department placed a sustained-release implant of the medication, naltrexone, via a quick, outpatient procedure into a soon-to-be released inmate at Louisiana State Penitentiary.
The purpose of the program is to demonstrate the effectiveness of the BioCorRx® Recovery Program for those suffering from alcohol and/or opioid use disorders. Through this pilot program, BioCorRx® intends to help those suffering while illustrating the cost and societal benefit of using the BioCorRx® Recovery Program in lieu of incarceration.
The volunteers selected by the medical staff at LADOC will receive the company’s BioCorRx Recovery Program which typically includes its proprietary cognitive behavioral therapy (CBT) modules, peer support, multi-month sustained release naltrexone implant and patient tracking.
“We are passionate about individuals overcoming addiction and have seen demonstrated results from our BioCorRx Recovery Program nationwide,” says BioCorRx CEO, President and Director, Brady Granier. “We are proud to partner with the Louisiana Department of Corrections to showcase the effectiveness of sustained release naltrexone combined with structured behavioral therapy and peer support.”
For the duration of the program, LADOC will provide oversight and monitoring of those volunteers that have been medically cleared by LADOC Medical Director to enter the program. The LADOC Medical Director plans to also collaborate directly with BioCorRx® for the behavioral components of the Recovery Program.
“Because of a collective effort with DOC Secretary Jimmy Leblanc, myself, and BioCorRx, we are moving forward with a proven treatment for opioid addiction in our correctional system,” said Louisiana State Representative Valarie Hodges. “I commend Secretary LeBlanc’s willingness to incorporate treatment into the justice system. BioCorRx’s protocol can negate the effects of opioids while cognitive behavioral therapy helps to rewire the brain’s coping mechanisms. This type of therapy has been used successfully for decades in many modern countries and I am tremendously grateful for the opportunity to finally implement the program in Louisiana. We have a chance to work with the criminal justice system as well as the families devastated by deadly drugs. This treatment has the ability to give people back their lives and help them become productive citizens. We should not be just punishing the crimes of those with addiction, but offering them hope of freedom and a path forward.”
The average cost of incarceration for Federal inmates was $100 per day in 2017. If adopted full-time, the BioCorRx® Recovery Program hopes to provide a cost-effective alternative to incarcerating drug offenders while preparing them for a clean reentry into society.
About BioCorRx, Inc.
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance abuse addiction and related disorders. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids, and can prevent opioid overdose following relapse. The second component of the program developed by BioCorRx Inc. is a Cognitive Behavioral Therapy (CBT) program tailored specifically for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
Crescendo Communications, LLC
(212) 671-1020 x304
Released May 2, 2019